このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Orthocell マネジメント

マネジメント基準チェック /14

現在、CEO に関する十分な情報がありません。

主要情報

Paul Anderson

最高経営責任者

AU$651.0k

報酬総額

CEO給与比率	64.5%
CEO在任期間	18.3yrs
CEOの所有権	1.8%
経営陣の平均在職期間	1.4yrs
取締役会の平均在任期間	6.3yrs

経営陣の近況

It's Probably Less Likely That Orthocell Limited's (ASX:OCC) CEO Will See A Huge Pay Rise This Year

Oct 25

Recent updates

It's Probably Less Likely That Orthocell Limited's (ASX:OCC) CEO Will See A Huge Pay Rise This Year

Oct 25

Here's Why We're Not At All Concerned With Orthocell's (ASX:OCC) Cash Burn Situation

May 31

Companies Like Orthocell (ASX:OCC) Are In A Position To Invest In Growth

Feb 15

How Does Orthocell's (ASX:OCC) CEO Salary Compare to Peers?

Dec 24

CEO報酬分析

Orthocell の収益と比較して、Paul Anderson の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Dec 31 2023	n/a	n/a	-AU$7m
Sep 30 2023	n/a	n/a	-AU$7m
Jun 30 2023	AU$651k	AU$420k	-AU$6m
Mar 31 2023	n/a	n/a	-AU$7m
Dec 31 2022	n/a	n/a	-AU$9m
Sep 30 2022	n/a	n/a	-AU$9m
Jun 30 2022	AU$531k	AU$380k	-AU$9m
Mar 31 2022	n/a	n/a	-AU$9m
Dec 31 2021	n/a	n/a	-AU$9m
Sep 30 2021	n/a	n/a	-AU$9m
Jun 30 2021	AU$1m	AU$375k	-AU$9m
Mar 31 2021	n/a	n/a	-AU$9m
Dec 31 2020	n/a	n/a	-AU$8m
Sep 30 2020	n/a	n/a	-AU$7m
Jun 30 2020	AU$578k	AU$370k	-AU$6m
Mar 31 2020	n/a	n/a	-AU$6m
Dec 31 2019	n/a	n/a	-AU$7m
Sep 30 2019	n/a	n/a	-AU$6m
Jun 30 2019	AU$582k	AU$365k	-AU$6m
Mar 31 2019	n/a	n/a	-AU$6m
Dec 31 2018	n/a	n/a	-AU$6m
Sep 30 2018	n/a	n/a	-AU$6m
Jun 30 2018	AU$597k	AU$365k	-AU$6m
Mar 31 2018	n/a	n/a	-AU$4m
Dec 31 2017	n/a	n/a	-AU$2m
Sep 30 2017	n/a	n/a	-AU$3m
Jun 30 2017	AU$533k	AU$350k	-AU$4m

報酬と市場: Paulの総報酬 ($USD 430.80K ) は、 Australian市場 ($USD 296.83K ) の同規模の企業の平均を上回っています。

報酬と収益: Paulの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Paul Anderson (58 yo)

18.3yrs

在職期間

AU$650,974

報酬

Mr. Paul Frederick Anderson serves as Chief Executive Officer of Orthocell Limited. Mr. Anderson has been Managing Director and Executive Director of Orthocell Limited since March 21, 2006. Mr. Anderson ha...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Paul Anderson	CEO, MD & Executive Director	no data	AU$650.97k	1.81% A$ 1.4m
Nicole Telford	Chief Financial Officer	no data	データなし	1.49% A$ 1.2m
Alex McHenry	Chief Operating Officer	5.4yrs	データなし	データなし
Ming Hao Zheng	Chief Scientific Officer and Member of Medical & Scientific Advisory Board	no data	データなし	1.63% A$ 1.3m
Tony Macintyre	Chief Technical Operations Officer	1.4yrs	データなし	データなし
Peter Webse	Company Secretary	1.3yrs	データなし	データなし

1.4yrs

平均在職期間

経験豊富な経営陣: OCCの経営陣は経験豊富とはみなされません ( 1.4年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Paul Anderson	CEO, MD & Executive Director	18.3yrs	AU$650.97k	1.81% A$ 1.4m
Ming Hao Zheng	Chief Scientific Officer and Member of Medical & Scientific Advisory Board	no data	データなし	1.63% A$ 1.3m
Fiona Wood	Independent Non-Executive Director	less than a year	AU$31.80k	0.0077% A$ 6.0k
Samuel Asculai	Chairman of Medical & Scientific Advisory Board	no data	データなし	データなし
Ray Crowe	Member of Medical & Scientific Advisory Board	no data	データなし	データなし
Gregory Janes	Member of Medical & Scientific Advisory Board	no data	データなし	データなし
David Wood	Member of Medical & Scientific Advisory Board	no data	データなし	データなし
Alan Wang	Member of Medical & Scientific Advisory Board	no data	データなし	データなし
John Van Der Wielen	Independent Non-Executive Chairman	less than a year	AU$658.12k	0.16% A$ 120.3k
Rocky Tuan	Member of Medical & Scientific Advisory Board	8.3yrs	データなし	データなし
Massimo Simion	Member of Medical & Scientific Advisory Board	6.3yrs	データなし	データなし
Giuseppe Luongo	Member of Medical & Scientific Advisory Board	6.3yrs	データなし	データなし

6.3yrs

平均在職期間

経験豊富なボード: OCCの取締役会は経験豊富であると考えられます ( 6.3年の平均在任期間)。

Orthocell マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

Orthocell Limited Announces Resignation of Matthew Callahan from the Board

Orthocell Limited Announces Changes to its Board

It's Probably Less Likely That Orthocell Limited's (ASX:OCC) CEO Will See A Huge Pay Rise This Year

Orthocell Limited Announces Board Changes

Less than half of directors are independent

Orthocell Limited Announces Board Changes

Recent updates

Orthocell Limited has completed a Follow-on Equity Offering in the amount of AUD 3.500001 million.

New minor risk - Shareholder dilution

Orthocell Limited has filed a Follow-on Equity Offering in the amount of AUD 3.5 million.

Orthocell Limited Announces Resignation of Matthew Callahan from the Board

Orthocell Limited Announces Changes to its Board

Orthocell Limited Provides Commercial Revenue Guidance for the Full Year 2023

It's Probably Less Likely That Orthocell Limited's (ASX:OCC) CEO Will See A Huge Pay Rise This Year

Orthocell Limited Announces Board Changes

Less than half of directors are independent

Orthocell Limited Announces Board Changes

Orthocell Limited, Annual General Meeting, Oct 31, 2023

Full year 2023 earnings released: AU$0.032 loss per share (vs AU$0.047 loss in FY 2022)

New minor risk - Financial data availability

Orthocell Limited Appoints John Van Der Wielen as Independent Non-Executive Chairman, Effective 1 June 2023

First half 2023 earnings released: AU$0.021 loss per share (vs AU$0.024 loss in 1H 2022)

We Think Orthocell (ASX:OCC) Can Afford To Drive Business Growth

Less than half of directors are independent

Orthocell Limited's Rotator Cuff Study Success with Cross-Over Patients

Orthocell Limited, Annual General Meeting, Oct 28, 2022

Full year 2022 earnings released: AU$0.047 loss per share (vs AU$0.048 loss in FY 2021)

We're Not Very Worried About Orthocell's (ASX:OCC) Cash Burn Rate

Orthocell Limited Announces the Completion of Its RemplirTM Nerve Reconstruction Study

Less than half of directors are independent

Orthocell (ASX:OCC) Is In A Good Position To Deliver On Growth Plans

Orthocell Ordinary Shares to Be Deleted from Other OTC

We're Not Worried About Orthocell's (ASX:OCC) Cash Burn

CEO, MD & Executive Director recently sold AU$552k worth of stock

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Full year 2021 earnings released: AU$0.047 loss per share (vs AU$0.036 loss in FY 2020)

Orthocell Limited Announces CelGro Nerve Study Results

Orthocell Limited Announces First Interim Data Read Out of All Patients in the Celgro® Nerve Regeneration Trial At 12 Months Post Treatment

Here's Why We're Not At All Concerned With Orthocell's (ASX:OCC) Cash Burn Situation

Orthocell Limited Announces New Collagen Rope Patent for CelGro Platform Technology

Celgro Study Results Open Up New US Market Access Strategy

Companies Like Orthocell (ASX:OCC) Are In A Position To Invest In Growth

Orthocell Limited Announces Publication of Successful Case Study Focussing on the Combination of Celgro® Collagen Medical Device and Autologous Tenocyte Implantation for the Surgical Repair of Large Degenerate Tear of the Gluteal Medius Tendo

Orthocell Ltd Receives US Market Clearance

Orthocell Limited Receives First US CelGro Product Approval

New 90-day high: AU$0.49

Orthocell Limited Receives Australian Market Approval for its Celgro, a Collagen Medical Device

How Does Orthocell's (ASX:OCC) CEO Salary Compare to Peers?

New 90-day high: AU$0.46

Orthocell Limited Announces Patient Enrolment for the Celgro® Nerve Regeneration Trial Is Now Complete

New 90-day low: AU$0.33

Orthocell Limited Announces CelGro Bone Regeneration in Dental & Orthopedic Applications

Full year earnings released - AU$0.036 loss per share

New 90-day high - AU$0.43

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

取締役

平均在職期間

マネジメント基準チェック /14